Tag: HPV Treatment NYC

Larry Jaeger is a Board Certified Dermatologist and the founder and owner of Central Park Medical Associates in New York. Larry Jaeger provides private and discreet testing and treatment for all HPV related diseases: HPV Treatment For Men: HPV – What We All Need To Know.

Does HPV infection increase cancer risk in men?

According to Larry Jaeger, the specific risks are different for men. Most of the time, HPV infection doesn’t cause any signs or symptoms in either sex, although some types of HPV cause genital warts.

Typically, the immune system eliminates the virus without treatment within about two years. Until the virus is gone, you can spread it to your sex partners.

Throat, Head & Neck Cancers: HPV

Larry Jaeger indicates that certain types of HPV, known as high-risk types, may cause persistent infection, which can gradually turn into cancer. Malignancies that can be caused by HPV include cancers of the vulva, vagina, penis, anus and oropharynx — the back of the mouth and upper part of the throat.

Men who have HIV — the virus that causes AIDS — and men who have sex with other men are at particular risk of anal, penile and throat cancers associated with persistent HPV infection. The rate of oropharyngeal cancers has been on the rise recently, especially in men.

HPV In Men: Treatment & Vaccine

Larry Jaeger relates that men can prevent the types of HPV that cause most genital warts and anal cancer by receiving an HPV vaccine. These were originally approved as a cervical cancer vaccine for girls and young women, and they’re now approved by the Food and Drug Administration for the prevention of anal, vulvar and vaginal cancers, too.

The vaccines are recommended for males ages 9 to 26. The best time to get the vaccine is before sexual activity begins. Although these vaccines are not yet approved for preventing HPV-related penile and oropharyngeal cancer, recent studies suggest that these vaccines may be effective for preventing these cancers as well.

You may also lower your risk of contracting HPV by using a condom every time you have sex. However, condom use isn’t considered a substitute for HPV vaccination in those who are eligible for the vaccine.

Larry Jaeger provides excellent dermatological diagnoses and treatments for patients at Central Park Medical Associates in New York. For over twenty-five years, Dr. Larry Jaeger has treated patients suffering from HPV related skin disorders and reveals new evidence of the effectiveness of HPV vaccines against cancer. “HPV Vaccine for Treating Cancer.”

How do HPV vaccines work?

Like other immunizations that guard against viral infections, HPV vaccines stimulate the body to produce antibodies that, in future encounters with HPV, bind to the virus and prevent it from infecting cells. The current HPV vaccines are based on virus-like particles (VLPs) that are formed by HPV surface components. VLPs are not infectious, because they lack the virus’s DNA. However, they closely resemble the natural virus, and antibodies against the VLPs also have activity against the natural virus. The VLPs have been found to be strongly immunogenic, which means that they induce high levels of antibody production by the body. This makes the vaccines highly effective.

The VLP technology that is used in the HPV vaccines was developed by NCI and other scientists. NCI licensed the technology to Merck and GSK to develop HPV vaccines for widespread distribution.

How effective are HPV vaccines?

Larry Jaeger maintains that HPV vaccines are highly effective in preventing infection with the types of HPV they target when given before initial exposure to the virus—which means before individuals begin to engage in sexual activity. In the trials that led to approval of Gardasil and Cervarix, these vaccines were found to provide nearly 100 percent protection against persistent cervical infections with HPV types 16 and 18 and the cervical cell changes that these persistent infections can cause. Gardasil 9 is as effective as Gardasil for the prevention of diseases caused by the four shared HPV types (6, 11, 16, and 18), based on similar antibody responses in participants in clinical studies. The trials that led to approval of Gardasil 9 found it to be 97 percent effective in preventing cervical, vulvar, and vaginal disease caused by the five additional HPV types (31, 33, 45, 52, and 58) that it targets (18).

To date, Larry Jaeger reports that protection against the targeted HPV types has been found to last for at least 8 years with Gardasil (19) and at least 9 years with Cervarix (20). The duration of protection with Gardasil 9 is not yet known. Long-term studies of vaccine efficacy that are still in progress will help scientists better understand the total duration of protection.

Who is eligible for HPV vaccines?

A clinical trial of Gardasil in men indicated that it can prevent anal cell changes caused by persistent infection and genital warts (21). Analyses of data from women participating in a clinical trial of Cervarix found that this vaccine can protect women against persistent HPV 16 and 18 infections in the anus (22) and the oral cavity (23).

The HPV vaccines are all designed to be given to people in three doses over a 6-month period. However, one study showed that women who received only two doses of Cervarix had as much protection from persistent HPV 16/18 infections as women who received three doses, and the protection was observed through 4 years of follow up (24). Even one dose provided protection. In other studies, young adolescents given two doses of Cervarix or Gardasil were found to have as strong an immune response as 15-to-25-year-olds who received three doses (25, 26). Based on the evidence to date, the World Health Organization has recommended two doses as the standard delivery for these vaccines, although in the United States three doses are still recommended.